Biointron’s Q3 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, 2 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: both from China.
Firsekibart (Jin Beixin)
Suvemcitug (Enzheshu)
Q3 2025 saw various acquisitions, collaborations, and licensing agreements of up to US$8 billion. Investment into antibody drug startups has focused on artificial intelligence platforms and antibody bispecific formats.
Gain exclusive insights into current trends such as:
2 novel antibody drugs approved for the first time in Q3
Top 10 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$8B
Current research into designing antibodies from scratch (de novo)
Immune cell engagers as a bispecific antibody format
A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q4 2025
Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends……
Fusion proteins are engineered molecules combining domains from two or more dist……
Antibody-drug conjugates (ADCs) rely critically on the chemical linker as the m……
Despite comprising the largest family of druggable membrane proteins, only three……
Your form has been submitted successfully.
DownloadYou can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
